Health-related technology is growing at an accelerating rate, as is its demand. The Food and Drug Administration (FDA), as the gatekeeper tasked with verifying the advertising for health products and the safety and efficacy of such technology, including new mobile platforms, has developed various new regulations in recent years. In this episode, McDermott IP partner Nathan S. Smith welcomes Vernessa Pollard and Veleka Peeples-Dyer, partners in McDermott’s Washington, DC office, to discuss five critical issues that life science companies should consider in dealing with the FDA. The podcast begins with a discussion of recent IP headlines from across the world with Sarah Bro.

Click here to listen to the podcast.